[go: up one dir, main page]

AR051589A1 - THERAPEUTIC AGENTS - Google Patents

THERAPEUTIC AGENTS

Info

Publication number
AR051589A1
AR051589A1 ARP050104358A ARP050104358A AR051589A1 AR 051589 A1 AR051589 A1 AR 051589A1 AR P050104358 A ARP050104358 A AR P050104358A AR P050104358 A ARP050104358 A AR P050104358A AR 051589 A1 AR051589 A1 AR 051589A1
Authority
AR
Argentina
Prior art keywords
cox
drug
therapeutic agents
composition according
granular composition
Prior art date
Application number
ARP050104358A
Other languages
Spanish (es)
Original Assignee
Boots Healthcare Int Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boots Healthcare Int Ltd filed Critical Boots Healthcare Int Ltd
Publication of AR051589A1 publication Critical patent/AR051589A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0007—Effervescent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Una composicion granular que comprende una pluralidad de gránulos de fusion solidificados que incluyen un fármaco Cox-2(ciclooxigenasa). Procedimiento, uso. Reivindicacion 12: Una composicion de acuerdo con la reivindicacion 11, en la cual el ingrediente farmacologicamente activo adicional comprende ibuprofen o paracetamol. Reivindicacion 22: Una forma de dosificacion unitaria para administracion oral, que comprende una composicion farmacéutica de acuerdo con cualquiera de las reivindicaciones 13 a 21, o una composicion granular tal como se definio en cualquiera de las reivindicaciones 1 a 12. Reivindicacion 32: Un método para mejorar la compresibilidad de un fármaco Cox-2 que comprende fundir el fármaco Cox-2 y solidificar el fármaco Cox-2 fundido.A granular composition comprising a plurality of solidified fusion granules that include a Cox-2 drug (cyclooxygenase). Procedure, use. Claim 12: A composition according to claim 11, wherein the additional pharmacologically active ingredient comprises ibuprofen or paracetamol. Claim 22: A unit dosage form for oral administration, comprising a pharmaceutical composition according to any one of claims 13 to 21, or a granular composition as defined in any one of claims 1 to 12. Claim 32: A method to improve the compressibility of a Cox-2 drug comprising melting the Cox-2 drug and solidifying the molten Cox-2 drug.

ARP050104358A 2004-10-19 2005-10-18 THERAPEUTIC AGENTS AR051589A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB0423103A GB0423103D0 (en) 2004-10-19 2004-10-19 Therapeutic agents

Publications (1)

Publication Number Publication Date
AR051589A1 true AR051589A1 (en) 2007-01-24

Family

ID=33462917

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP050104358A AR051589A1 (en) 2004-10-19 2005-10-18 THERAPEUTIC AGENTS

Country Status (4)

Country Link
EP (1) EP1811964A1 (en)
AR (1) AR051589A1 (en)
GB (1) GB0423103D0 (en)
WO (1) WO2006043025A1 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0519350D0 (en) * 2005-09-22 2005-11-02 Boots Healthcare Int Ltd Therapeutic agents
RU2010128019A (en) * 2007-12-08 2012-01-20 Байер Шеринг Фарма Акциенгезельшафт (DE) ORAL DISPERSABLE TABLET
WO2011050944A1 (en) * 2009-10-28 2011-05-05 Ratiopharm Gmbh Formulations containing celecoxib
NZ603173A (en) 2010-05-10 2014-10-31 Euro Celtique Sa Manufacturing of active-free granules and tablets comprising the same
JP5840201B2 (en) 2010-05-10 2016-01-06 ユーロ−セルティーク エス．エイ． Combination of granules loaded with active agent and additional active agent
KR20130030260A (en) 2010-05-10 2013-03-26 유로-셀티큐 에스.에이. Pharmaceutical compositions comprising hydromorphone and naloxone
WO2014033526A1 (en) 2012-08-27 2014-03-06 Cadila Healthcare Limited Pharmaceutical compositions of etoricoxib
WO2015004505A1 (en) * 2013-07-11 2015-01-15 More Pharma Corporation, S. De R.L. De C.V. Synergistic combination of paracetamol/celecoxib for the treatment of inflammatory pain
DE112014005175T5 (en) 2013-11-13 2016-07-21 Euro-Celtique S.A. Hydromorphone and naloxone for the treatment of pain and opioid bowel dysfunction syndrome
CN108057025A (en) * 2017-12-08 2018-05-22 佛山市弘泰药物研发有限公司 A kind of Etoricoxib oral disintegrating tablet and preparation method thereof
TW201936175A (en) * 2018-02-21 2019-09-16 日商日本新藥股份有限公司 Granular composition, production method for granular composition, and dissolution property improvement method for granular composition
PE20251234A1 (en) 2023-10-05 2025-04-29 Laboratorios Silanes S A De C V CELECOXIB-ACETAMINOPHEN COMBINATION WITH ENHANCED STABILITY AND PROCEDURE FOR ITS PREPARATION

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3833448A1 (en) * 1988-10-01 1990-04-12 Hoechst Ag METHOD OF OBTAINING IBUPROFEN FOR DIRECT TESTING
CZ20012875A3 (en) * 1999-12-08 2002-02-13 Pharmacia Corporation Polymorphous crystalline forms of celecoxib
NZ519485A (en) * 1999-12-09 2004-02-27 Boots Co Plc Compressed tablet composition comprising a solidified melt granule of NSAID and silicon dioxide as an extra granular component
GB0113839D0 (en) * 2001-06-07 2001-08-01 Boots Co Plc Therapeutic agents
GB0113841D0 (en) * 2001-06-07 2001-08-01 Boots Co Plc Therapeutic agents

Also Published As

Publication number Publication date
GB0423103D0 (en) 2004-11-17
EP1811964A1 (en) 2007-08-01
WO2006043025A1 (en) 2006-04-27

Similar Documents

Publication Publication Date Title
MX2009000730A (en) Controlled release formulations and associated methods.
EP1909772A4 (en) FORMULATION FOR TRANSDERMAL DRUG DELIVERY
WO2007072503A3 (en) Combinations for managing inflammation and associated disorders
AR051589A1 (en) THERAPEUTIC AGENTS
HRP20060147B1 (en) CONTROLLED RELEASE THERAPY SYSTEM FOR Oral Use
ECSP056076A (en) SUPPLY SYSTEM FOR DRUG AND CELL THERAPY
AR078846A1 (en) COMPOSITION FOR THE TREATMENT OF ALZHEIMER'S DISEASE
PE20081301A1 (en) ESTROGEN BI-LAYER TABLETS / SELECTIVE ESTROGEN RECEPTOR MODULATORS (SERM) AND ESTROGEN / PROGESTIN
ATE355065T1 (en) THERAPEUTIC COMPOSITIONS CONSISTING OF ANTIHYPOTENSIVES AND ANTIANGIOGENICS
CO5190672A1 (en) COMPOSITION FOR ORAL DOSAGE, INSTANT DISSOLUTION
WO2009088414A3 (en) Oral pharmaceutical dosage forms
DE60032749D1 (en) STABILIZED PHARMACEUTICAL COMPOSITION CONTAINING AN NON-TEROID INFUSE-INFLAMMATIVE AGGREGATE AND PROSTAGLANDIN
BRPI0515372A (en) composition, and method for providing an anesthetic effect to a site in an individual
IL195269A0 (en) Pharmaceutical formulations for the sustained release of active ingredient(s), as well as their applications, especially therapeutic
PT1827396T (en) Oral medicament for the modified release of at least one active principle, in multimicrocapsule form
PA8594801A1 (en) PALANOSETRON LIQUID PHARMACEUTICAL FORMULATIONS
EP1807146A4 (en) COMPOSITION FOR IMPROVING THE EFFICACY OF DRUG DELIVERY
JP2015532296A5 (en)
AR060019A1 (en) PHARMACEUTICAL COMPOSITION, PRODUCT AND TREATMENT METHOD FOR A COGNITIVE DISORDER AND USES OF AN ACETILCOLINESTERASE INHIBITOR AND A 5- HT6 ANTAGONIST IN THE MANUFACTURE OF A MEDICINAL PRODUCT FOR THE TREATMENT OF A COGNITIVE DISORDER
FR19C1030I1 (en) DRUG DELIVERY SYSTEM FOR DELIVERING POORLY WATER SOLUBLE PHARMACEUTICALLY ACTIVE SUBSTANCES
CL2008000750A1 (en) METHOD FOR THE ADMINISTRATION OF A WEEKLY DOSE OF 2- [6- (3-AMINO-PIPERIDIN-1-IL) 3-METHYL-2,4 DIOXO-3,4 DIHYDRO-2H-PIRIMIDIN-1-IL METIL] -4 FLUORO-BENZONITRILE; PHARMACEUTICAL COMPOSITION OF AN INDIVIDUAL DOSAGE FORM OF SUCH COMPOUND; AND HIS
PE20120791A1 (en) COMPOSITIONS AND METHODS FOR PROLONGED THERAPY WITH AMINOPYRIDINES
SE0200895D0 (en) New pharmaceutical composition
AR046036A1 (en) RISEDRONATE COMPOSITIONS AND METHODS FOR USE
BR0112847A (en) Use of a solid dosage form

Legal Events

Date Code Title Description
FB Suspension of granting procedure